Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Duke who wrote (2290)	4/6/1999 2:27:00 PM
From: RockDoc	Read Replies (1) \| Respond to of 4140

First Impression Yes, I suppose this company poses a potential threat as a competitor to SNRS. They are a privately held company and in phase 3 trials. Only 65 eyes so far (not a very big "N") and 12 months of data (not a very long time). What is their source of funding to bring the phase 3 trials to completion? They are probably at least 2 years behind SNRS for FDA approval if Phase 3 just began. The technology can allegedly treat hyperopia up to +4 diopters (low to mid hyperopia, prsbyopia, and overcorrection of excimer laser treatment for myopia, sparing the optical zone (essentially same as SNRS). It appears from reading on their website that the technology (RFK) is MORE INVASIVE than LTK, requres more surgical time for the procedure, and has a higher risk of post-op infection, pain, and other complications. The machines appear to be more portable and cheaper than SNRS's laser. A question would remain of how much training and surgical skill is required to perform the procedure. We need more information, data and research before we can conclude whether this poses a real threat to SNRS or not. Perhaps they are exhibiting at ASCRS this month. It would be a good opportunity for whomever is attending to ask around, including the SNRS personnel, about the potential for competition. I'm sure the shorts will jump all over this. But it really is premature to draw ANY conclusions. We need more information. Meanwhile, SNRS is on the verge of FDA approval and will have a considerable head start in market entry and penetration. All good news for us. The ROCKSTER